Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines

Johannes Vieweg, Felicia M. Rosenthal, Rajat Bannerji, Warren D W Heston, William R. Fair, Eli Gilboa, Eli Gilboa

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.

Original languageEnglish
Pages (from-to)1760-1765
Number of pages6
JournalCancer Research
Volume54
Issue number7
StatePublished - Apr 1 1994
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Prostatic Neoplasms
Cytokines
Genes
Neoplasms
Prostate
Immunologic Memory
Active Immunotherapy
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor
Interferons
Interleukin-2
Adenocarcinoma
Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vieweg, J., Rosenthal, F. M., Bannerji, R., Heston, W. D. W., Fair, W. R., Gilboa, E., & Gilboa, E. (1994). Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Research, 54(7), 1760-1765.

Immunotherapy of prostate cancer in the dunning rat model : Use of cytokine gene modified tumor vaccines. / Vieweg, Johannes; Rosenthal, Felicia M.; Bannerji, Rajat; Heston, Warren D W; Fair, William R.; Gilboa, Eli; Gilboa, Eli.

In: Cancer Research, Vol. 54, No. 7, 01.04.1994, p. 1760-1765.

Research output: Contribution to journalArticle

Vieweg, J, Rosenthal, FM, Bannerji, R, Heston, WDW, Fair, WR, Gilboa, E & Gilboa, E 1994, 'Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines', Cancer Research, vol. 54, no. 7, pp. 1760-1765.
Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gilboa E et al. Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Research. 1994 Apr 1;54(7):1760-1765.
Vieweg, Johannes ; Rosenthal, Felicia M. ; Bannerji, Rajat ; Heston, Warren D W ; Fair, William R. ; Gilboa, Eli ; Gilboa, Eli. / Immunotherapy of prostate cancer in the dunning rat model : Use of cytokine gene modified tumor vaccines. In: Cancer Research. 1994 ; Vol. 54, No. 7. pp. 1760-1765.
@article{33d221fe2a34418297819e082509039e,
title = "Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene modified tumor vaccines",
abstract = "Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.",
author = "Johannes Vieweg and Rosenthal, {Felicia M.} and Rajat Bannerji and Heston, {Warren D W} and Fair, {William R.} and Eli Gilboa and Eli Gilboa",
year = "1994",
month = "4",
day = "1",
language = "English",
volume = "54",
pages = "1760--1765",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Immunotherapy of prostate cancer in the dunning rat model

T2 - Use of cytokine gene modified tumor vaccines

AU - Vieweg, Johannes

AU - Rosenthal, Felicia M.

AU - Bannerji, Rajat

AU - Heston, Warren D W

AU - Fair, William R.

AU - Gilboa, Eli

AU - Gilboa, Eli

PY - 1994/4/1

Y1 - 1994/4/1

N2 - Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.

AB - Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028297315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028297315&partnerID=8YFLogxK

M3 - Article

C2 - 8137291

AN - SCOPUS:0028297315

VL - 54

SP - 1760

EP - 1765

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -